Treosulfan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 428 publications

Pediatric Nonmalignant Hematopoietic Cell Transplantation in the Era of Precision Conditioning and Gene Therapy.

Pediatric Nonmalignant Hematopoietic Cell Transplantation in the Era of Precision Conditioning and Gene Therapy.

Journal: Pediatric annals

Published: September 03, 2026

Expanding the conditioning armamentarium in adult acute lymphoblastic leukaemia: is treosulfan ready to challenge total body irradiation?

Expanding the conditioning armamentarium in adult acute lymphoblastic leukaemia: is treosulfan ready to challenge total body irradiation?

Journal: Bone marrow transplantation

Published: May 31, 2026

Mitigating HLA Disparity in AML Transplantation: Comparable Outcomes After Haploidentical and 9/10 Mismatched Unrelated Donor Transplantation With Treosulfan and PTCy.

Mitigating HLA Disparity in AML Transplantation: Comparable Outcomes After Haploidentical and 9/10 Mismatched Unrelated Donor Transplantation With Treosulfan and PTCy.

Journal: American journal of hematology

Published: May 27, 2026

Alternative Conditioning Regimens for Hemoglobinopathy Gene Therapy: Balancing Efficacy, Toxicity, and the Next Frontier.

Alternative Conditioning Regimens for Hemoglobinopathy Gene Therapy: Balancing Efficacy, Toxicity, and the Next Frontier.

Journal: Blood advances

Published: May 21, 2026

Treosulfan or busulfan plus clofarabine as reduced intensity conditioning regimen before allotransplant for adults with myeloid malignancies.

Treosulfan or busulfan plus clofarabine as reduced intensity conditioning regimen before allotransplant for adults with myeloid malignancies.

Journal: Bone marrow transplantation

Published: May 19, 2026

A liquid chromatography-tandem mass spectrometry method for therapeutic drug monitoring of treosulfan.

A liquid chromatography-tandem mass spectrometry method for therapeutic drug monitoring of treosulfan.

Journal: Laboratory medicine

Published: April 28, 2026

Treosulfan-Based Conditioning in Allogeneic Stem Cell Transplantation for Myelofibrosis: A Systematic Review.

Treosulfan-Based Conditioning in Allogeneic Stem Cell Transplantation for Myelofibrosis: A Systematic Review.

Journal: Journal of clinical medicine

Published: April 10, 2026

Fludarabine-Treosulfan (FT10) Conditioning in Older AML Patients Undergoing Haploidentical Transplantation: A Prospective Italian Study With External Comparison to the Haplo-UK Reduced-Intensity Conditioning Cohort.

Fludarabine-Treosulfan (FT10) Conditioning in Older AML Patients Undergoing Haploidentical Transplantation: A Prospective Italian Study With External Comparison to the Haplo-UK Reduced-Intensity Conditioning Cohort.

Journal: Transplantation and cellular therapy

Published: April 02, 2026

Fludarabine combined with treosulfan or total body irradiation as a conditioning therapy before allogeneic hematopoietic stem cell transplantation in acute lymphoblastic leukemia. A retrospective matched-pair analysis from the ALWP of the EBMT.

Fludarabine combined with treosulfan or total body irradiation as a conditioning therapy before allogeneic hematopoietic stem cell transplantation in acute lymphoblastic leukemia. A retrospective matched-pair analysis from the ALWP of the EBMT.

Journal: Bone marrow transplantation

Published: March 15, 2026

Impact of Dyslipidemia on Allogeneic Transplantation Outcomes and Cardiovascular Mortality in Patients with Acute Leukemias in the Post-Transplant Cyclophosphamide Era.

Impact of Dyslipidemia on Allogeneic Transplantation Outcomes and Cardiovascular Mortality in Patients with Acute Leukemias in the Post-Transplant Cyclophosphamide Era.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: March 11, 2026

A phase II multicenter prospective study to evaluate the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning regimen in allogeneic hematopoietic stem cell transplantation for AML patients aged 40-65 in first complete remission.

A phase II multicenter prospective study to evaluate the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning regimen in allogeneic hematopoietic stem cell transplantation for AML patients aged 40-65 in first complete remission.

Journal: Bone marrow transplantation

Published: January 21, 2026

Treosulfan-based conditioning for hematopoietic stem cell transplantation in mucopolysaccharidosis: a pilot study.

Treosulfan-based conditioning for hematopoietic stem cell transplantation in mucopolysaccharidosis: a pilot study.

Journal: International journal of hematology

Published: January 08, 2026

Showing 1-12 of 428

Last Updated: 09/26/2026